All In Biotech

Drug Trial Radar · NCT00998283

Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects

A Randomized, Double-Blind, Placebo-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Korean Subjects

Last checked: Nov 20, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Oct 2009

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Sponsor type
Industry
First posted
Oct 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

* Study Design * Randomized, Double-blind, Placebo-controlled, escalating single-dose design. * Five ascending dose cohorts. * In each cohort, subjects will be randomized to receive a single dose of HM10460A or placebo (negative control) * Objectives * The primary objective of the study is to assess the safety and tolerability of single escalating subcutaneous doses of HM10460A in healthy adult Korean Subjects

Conditions

  • Healthy

Interventions

  • HM10460A 5μg/kgDrug

    Subcutaneously administrate at 0 hour on Day 1

  • HM10460A 15μg/kgDrug

    Subcutaneously administrate at 0 hour on Day 1

  • HM10460A 45μg/kgDrug

    Subcutaneously administrate at 0 hour on Day 1

  • HM10460A 135μg/kgDrug

    Subcutaneously administrate at 0 hour on Day 1

  • HM10460A 350μg/kgDrug

    Subcutaneously administrate at 0 hour on Day 1

  • PlaceboDrug

    Subcutaneously administrate at 0 hour on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety data, including physical examinations (to include injection site reactions and splenic evaluations), laboratory evaluations, ECGs, vital signs, and adverse effects (AEs)Time frame: Time point of collection, where appropriate
  2. Samples for immunogenicityTime frame: Time point of collection, where appropriate

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.